All news

Boston Scientific discloses $642,000 in quarterly lobbying spend

Alpha Vantage · Quiver Quantitative · · AI-summarised by FinFlash

Boston Scientific Corporation disclosed $642,000 in lobbying expenditures for Q3 2026, spanning medical device regulation, patient access, tax provisions and supply chain resiliency. Filings cite work on the National Defense Authorization Act, breakthrough product access legislation and ethylene oxide emissions rules. Analyst consensus shows 25 buy ratings and a $59.55 target versus a $43.00 price, implying 38.5% upside.

Read original source

BSX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.